Modern Tendencies of Synovial Fluid Substituting Drugs Based on Bound Hyaluronic Acid Use in Treatment of Patients with Loco-Motor System Pathology and Injuries

Full Text


Analysis of literature on hyaluronic acid role and properties as well as on the use of synovial fluid substituting drugs based on bound hyaluronic acid (HA) shows the significance of this type of therapy for the arrest of articular and periarticular pain syndrome, and high efficacy in complex treatment of osteoarthritis. Recent data enabled to understand better the mechanisms of HA metabolism and to determine the advantages HA drugs use depending on the production technology, molecular weight and other pharmacodynamics properties.

Full Text

Современные тенденции использования средств, замещающих синовиальную жидкость, на основе связанной гиалуроновой кислоты в лечении пациентов с травмами и заболеваниями опорно-двигательного аппарата

About the authors

M. A Strakhov


A. V Skoroglyadov


  1. Онущенко И. А., Петрова Н. Н., Васильев В. В. и др. Качество жизни больных остеоартрозом. В кн: Материалы Юбилейной конференции, посвященной 15-летию НИИ клинической и экспериментальной ревматологии РАМН. Волгоград; 2000; 105–6.
  2. Цапина Т.Н., Эрдес Ш. Ф., Слизкова К.Ш. Качество жизни больных остеоартрозом. Научно-практическая ревматология. 2004; 2: 4.
  3. Лила А.М. Оптимизация лечения остеоартроза: препараты гиалуроновой кислоты. Consilium Medicum. 2008; 10 (7): 124–7.
  4. Gigante A., Callegari L. The Role of intra-articular hyaluronan in the treatment of osteoarthritis. Rheumatol. Int. 2011; 31 (4): 427–44.
  5. Belcher C., Yaqub R., Fawthrop F., Bayliss M., Doherty M. Synovial fluid chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in arthritic and normal knees. Ann. Rheum. Dis. 1997; 56 (5): 299–307.
  6. Хабаров В.Н., Бойков П.Я., Селянин М.А. Гиалуроновая кислота. М.: Практическая медицина. 2012.
  7. Photocurable glycosaminoglycan derivatives, crosslinked glycosaminoglycans and method of production thereof. Patent US 5462976 A.
  8. Беленький А.Г. Препараты гиалуроновой кислоты в лечении остеоартроза: Учебное пособие. М.; 2005.
  9. Lussier A., Cividino A.A., McFarlane C.A., Olszynski W.P., Potashner W.J., De Mйdicis R. Viscosupplementation with Hylan for the treatment of osteoarthritis findings from clinical practice in Canada. J. Rheumatol. 1996; 23 (9): 1579–85.
  10. Listrat V., Ayral X., Patarnello F., Bonvarlet J.P., Simonnet J., Amor B., Dougados M. Arthroscopic evaluation of potential structure modifyting activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartilage. 1997; 5 (3): 153–60.
  11. Dougados M., Nguyen M., Listrat V., Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarhtritis of the knee: a 1 year placebo controlled trial. Osteoarthritis Cartilage. 1993; 1 (2): 97–103.
  12. Aihara S., Murakami N., Ishii R., Kariya K., Azuma Y., Hamada K., Umemoto J., Maeda S. Effects of sodium hyaluronate on the nociceptive response of rats with experimentally induced arthritis. Nihon Yakurigaku Zasshi.1992; 100: 359–65.
  13. Pullman-Mooar S., Mooar P., Sieck M. Are there distinctive inflammatory flares of synovitis after hylan GF intraarticular injections? Arthr. Rheum. 1999; 42 (Suppl. 9): S295.
  14. Puttic M.P., Wade J.P., Chalmers A., Connell D.G., Rangno K.K. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J. Rheum. 1995; 22: 1311–14.
  15. Bernardeu C., Bucki B., Liote F. Acute arthritis after intraarticular hyaluronate injection: onset of effusion without crystal. Ann. Rheum. Dis. 2001; 60: 518–20.
  16. Moore A.R., Willoughby D.A. Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. Int. J. Tissue React. 1995; 17 (4): 153–6.
  17. Доклад Dr Massimo Toffolo,
  18. Лила А.М. Остеоартроз коленных суставов: лечение с позиций доказательной медицины. Новые Санкт-Петербургские врачебные ведомости. 2006; 35 (1): 38–44.
  19. Supartz Prescribing Information. Memphis, TN: Smith & Nephew, Inc; 2007.
  20. P080020c.pdf. Accessed April 6, 2011.
  21. Adams M.E., Atkinson M.H., Lussier A.J., Schulz J.I., Siminovitch K.A., Wade J.P. et al. The role of viscosupplementation with hylan G-F 20 (Synvisc®) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage. 1995; 3 (4): 213–26.
  22. Caborn D., Rush J., Lanzer W., Parenti D., Murray C. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J. Rheum. 2004; 31: 333–43.
  23. Wadell D.D., Brocker D.C. Total knee replacement delayed with hylan G-F 20 use in patients with grade IV osteoarthritis. J. Managed Care Pharmacy. 2001;13 (2): 113–21.
  24. Wang Y., Hall S., Hanna F., Wluka A.E., Grant G., Marks P., Feletar M., Cicuttini F.M. Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMC Musculoskelet. Disord. 2011; 12: 195.
  25. Migliore A., Bizzi E., Massafra U., Bella A., Piscitelli P., Laganа B., Tormenta S. The impact of treatment with hylan G-F 20 on progression to total hip arthroplasty in patients with symptomatic hip OA: a retrospective study. Curr. Med. Res. Opin. 2012; 28 (5): 755–60.
  26. Raman R., Dutta A., Day N., Sharma H.K., Shaw C.J., Johnson G.V. Efficacy of Hylan G-F 20 and Sodium Hyaluronate in the treatment of osteoarthritis of the knee — a prospective randomized clinical trial. Knee. 2008:15 (4); 318–24.
  27. Raynauld J.P., Torrance G.W., Band P.A., Gold- smith C.H., Tugwell P., Walker V., Schultz M., Bellamy N. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage. 2002; 10 (7): 506–17.
  28. Bellamy N., Campbell J., Robinson V., Gee T., Bourne R., Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database of Syst Rev. 2006; 2: CD005321.
  29. Waddell D.D., Bricker D.C. Hylan G-F 20 tolerability with repeat treatment in a large orthopedic practice: a retrospective review. J. Surg. Orthop. Adv. 2006; 15 (1): 53–9.
  30. Munteanu S.E., Zammit G.V., Menz H.B. Landorf K.B., Handley C.J., Elzarka A., Deluca J. Effectiveness of intra- articular hyaluronan (Synvisc, hylan G-F 20) for the treatment of first metatarsophalangeal joint osteoarthritis: a randomised placebo-controlled trial. Ann. Rheum. Dis. 2011; 70 (10): 1838–41.
  31. Li P., Raitcheva D., Hawes M., Moran N., Yu X., Wang F., Matthews G.L. Hylan G-F 20 maintains cartilage integrity and decreases osteophyte formation in osteoarthritis through both anabolic and anti-catabolic mechanisms. Osteoarthritis Cartilage. 2012; 20: 1336–46
  32. Henrotin Y., Chevalier X., Deberg M., Balblanc J.C., Richette P., Mulleman D. et al. Early decrease of serum biomarkers of type II collagen degradation (coll2-1) and joint inflammation (Coll2-1 NO2) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the biovisco study. J. Orthop. Res. 2013; 31 (6): 901–7.
  33. Chevalier X., Jerosch J., Goupille P., van Dijk N., Luyten F.P., Scott D.L., Bailleul F., Pavelka K. Single, intra- articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomized, multicentre, double-blind, placebo controlled trial. Ann. Rheum. Dis. 2010; 69: 113–9



Abstract: 127


Article Metrics

Metrics Loading ...



  • There are currently no refbacks.

Copyright (c) 2013 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies